This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe Spring
3 days in-person. 3 days virtually.
March 20–22, 2023 | Basel, SwitzerlandMarch 28–30, 2023 | Digital

Isanans Pharma



Isanans is a recently established biotech company focusing on inflammatory eye disorders. The lead asset is a small molecule KCa3.1 blocker and has in animal models demonstrated significant anti-inflammatory effect and to be well-tolerated. The molecule is being developed as a topical/local treatment and the intention is to demonstrate cPoP in the most cost-efficient way, and then broaden up to a number of relevant indications after human effect has been demonstrated.

Presenter: Kamilla Rolsted, Co-founder and CEO, Isanans Pharma